Day: February 9, 2024

L’Oréal Groupe signs an agreement for an exclusive worldwide licence agreement with Miu Miu

Written by Customer Service on February 9, 2024. Posted in Mergers And Acquisitions.

L’Oréal Groupe and Prada S.p.A announced today the signature of a worldwide long-term license agreement for the creation, development, and distribution of the luxury beauty products for the Miu Miu brand. Following the successful collaboration with Prada brand, Miu Miu is now joining the L’Oréal Luxe division for a new beauty chapter. Miu Miu was born in 1993 from the independent and unconventional spirit of Miuccia Prada. Since then, this unique luxury brand has been the incarnation of experimental creativity in fashion. With a light but always sophisticated touch, Miu Miu leads fashion, representing the courage to take risks, a razor-sharp instinct to respond to shifts in contemporary fashion and culture. The brand is an infinite source of inspiration for beauty and will resonate with an emancipated, sophisticated and conscious audience....

Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT

Written by Customer Service on February 9, 2024. Posted in Earnings Releases And Operating Results.

HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full year. Adjusted for the sale of assets in the second quarter, operating revenues were NOK 194.9m for the full year, representing an increase compared to 2022 of 38 percent. Cash and cash equivalents increased by NOK 6.2m during the quarter, leaving total holding at NOK 23.9m at the end of the year, compared to NOK 32.4m at the end of 2022. Including credit facilities, HBC had NOK 62.5m in free liquidity as of the end of 2023. Jon Olav Ødegård, CEO of HBC says: “I am pleased to point out the investment in HBC through a new class of preference shares, settled by converting NOK 144 million of debt, demonstrates our commitment to financial stability and growth. We closed the transaction in early January 2024, resulting in a strong...

Yara reports increased deliveries and improved margin trend

Written by Customer Service on February 9, 2024. Posted in Earnings Releases And Operating Results.

Oslo, 9 February 2024: Fourth-quarter EBITDA1 was USD 586 million, compared with USD 1,067 million a year earlier. Net income was USD 246 million (USD 0.96 per share) compared with USD 766 million (USD 3.02 per share) in fourth quarter 2022. The main elements of the fourth-quarter results are:EBITDA1 of 586 MUSD, improving trend since 2Q23 4% increase in crop nutrition deliveries 1 BUSD full-year free cash flow2 Increased buying activity and rising prices indicate volume catch-up in 1H2024 NOK 5 per share annual dividend proposed“Following strong financial results in 2022, the results in 2023 were impacted by significantly lower market prices and one-off position effects. EBITDA for the quarter is 586 MUSD and I am pleased to see an improving trend since second quarter, and a positive market trend going into 2024. We propose an annual...

Coloplast A/S – Interim Financial Report, Q1 2023/24

Written by Customer Service on February 9, 2024. Posted in Earnings Releases And Operating Results.

Q1 2023/24Interim financial results, Q1 2023/241 October 2023 – 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin1) of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies.Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 9% (Advanced Wound Dressings 9%) and Interventional Urology 5%. Solid start in Chronic Care, driven by broad-based growth in Emerging markets and Europe. The Ostomy Care business in China posted mid-single digit growth, in line with expectations. Growth in Continence Care was driven by the intermittent catheters portfolio, including contribution from LujaTM, the new male intermittent catheter with...

Coloplast launches Peristeen® Light for people with bowel disorders

Written by Customer Service on February 9, 2024. Posted in Public Companies.

Peristeen LightPeristeen Light is designed to bring relief. It is a hand-held, low-volume transanal irrigation device that instills water into the rectum, thereby evacuating the stool from the lower bowel.The new transanal irrigation device is designed to help people facing defecation issues or stool leakage. It is estimated that 10-15% of the world’s population are affected by chronic constipation1 and that 6% struggle with faecal incontinence2, both of which can cause physical discomfort and mental distress3. Although transanal irrigation treatment can help, the journey to treatment is often challenging with many patients left untreated. For some patients, symptoms are not considered severe enough, while others can feel intimidated by the existing treatments and product offerings, often leading to social isolation4. “Transanal...

JANUARY VOLUMES: GOOD START TO THE YEAR

Written by Customer Service on February 9, 2024. Posted in Public Companies.

INVESTOR NEWS no. 07 – 9 February 2024 Ferry – freight: Total volumes in January 2024 were 10.1% above 2023 and up 5.1% adjusted for the addition of Strait of Gibraltar routes and closure of the Calais-Tilbury route. North Sea volumes were above 2023 partly due to the addition of further automotive volumes on one route. Mediterranean volumes were below 2023 following a slow start as volumes picked up through the month. Channel volumes were above 2023 driven by the Dover Strait routes. Baltic Sea volumes were also above 2023 despite reduction of capacity between Estonia and Sweden compared to 2023. For the last twelve months 2024-23, the total transported freight lane metres decreased 6.7% to 38.7m from 41.6m in 2023-22. Ferry – passenger: The number of passengers in January 2024 were 87.4% above 2023 and up 2.7% adjusted...

JANUARY VOLUMES: GOOD START TO THE YEAR

Written by Customer Service on February 9, 2024. Posted in Public Companies.

Invitation to presentation of NORBIT’s fourth quarter and preliminary annual results 2023, 15 February 2024

Written by Customer Service on February 9, 2024. Posted in Public Companies.

Trondheim, Norway, 9 February 2024: NORBIT, a global provider of tailored technology to carefully selected applications, will announce its results for the fourth quarter of 2023 on Thursday 15 February 2024. As part of the presentation, the company will also announce its strategic and financial plan for the period 2024 and beyond. The interim report for the fourth quarter and the presentation material will be available from 07:00 am CET at the company’s homepage, www.norbit.com and Oslo Stock Exchange’s news site, www.newsweb.no. CEO Per Jørgen Weisethaunet and CFO Per Kristian Reppe will present the results at 09:00 am CET. The presentation will be hosted by Arctic Securities via a live webcast. Please use the following link to register for the webcast: https://forms.office.com/e/fakCZYG9K2 For further queries, please contact:Per...

LAUNCH OF SHARE BUYBACK PROGRAMME

Written by Customer Service on February 9, 2024. Posted in Public Companies.

COMPANY ANNOUNCEMENT no. 06 – 9 February 2024 The Board of Directors of DFDS A/S (“DFDS”) has decided to initiate a share buyback programme of up to DKK 431 million during the period until 30 September 2024. The programme will be executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). PurposeThe purpose of the programme is to adjust the capital structure of DFDS, ultimately through cancellation of repurchased shares, and to meet obligations under DFDS’ share-based incentive schemes. TermsThe share buyback programme is implemented with the following terms:The programme will be executed during the period from 12 February 2024 and until 31 December 2024; DFDS may repurchase...

IBA acquires Radcal Corporation to expand Medical Imaging Quality Assurance offering and strengthen US presence

Written by Customer Service on February 9, 2024. Posted in Mergers And Acquisitions.

Highly complementary acquisition continues IBA’s expansion strategy to lead the Radiotherapy, Medical Imaging Dosimetry and Quality Assurance markets globally Louvain-la-Neuve, Belgium, February 9, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, announced today it has signed an agreement to acquire all the assets of Radcal Corporation, a leader in diagnostic X-ray measurement based in California, USA. Through this acquisition, IBA will further strengthen its Medical Imaging Quality Assurance offering and its presence in the US market. Closing is expected on February 29, 2024. The acquisition is expected to be revenue accretive and EBIT positive from 2024. Radcal is a pioneer in the X-ray imaging market,...

Day: February 9, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice